Abstracts tagged "cytokines"

Abstract Number: 060 • 2023 Pediatric Rheumatology Symposium
Are the Levels of Cytokines Good Biomarkers for Smoldering Disease Activity in Childhood-Takayasu Arteritis?
Gleice Clemente¹, Maria Teresa Terreri², Bruno Gualano³, Clovis Silva⁴ and Alexandre Wagner De Souza¹, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²UNIFESP, São Paulo, Brazil, ³Universidade de São Paulo, São Paulo, ⁴Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Biomarkers for disease activity in adult Takayasu arteritis (TA) have been studied exhaustively, but there are inconsistencies among the studies (1). Childhood-TA (c-TA) differs…
Abstract Number: 113 • 2023 Pediatric Rheumatology Symposium
Proportion of Patients with a Polyphasic Disease Course in Systemic-onset Juvenile Idiopathic Arthritis May Be Higher in the Age of Cytokine Inhibitors
Itay Marmor¹, Rotem Semo Oz², Amir hendel³, Guy Hazan⁴, Kevin Baszis⁵, Anthony French⁵, Cuoghi Edens⁶, Irit Tirosh⁷, Yonatan Butbul Aviel⁸, Liora Harel⁹ and Gil Amarilyo¹⁰, ¹Dana-Dwek Children's Hospital, Hod Hasharon, Israel, ²Sheba medical center, Herzelyia, Israel, ³Tel Aviv University, Tel Aviv, Israel, ⁴Soroka University Medical Center, Be'er Sheva, Israel, ⁵Washington University School of Medicine, St Louis, MO, ⁶University of Chicago, Chicago, IL, ⁷Sheba Medical Center, Savyon, Israel, ⁸Rambam Medical center, Haifa, Israel, ⁹Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel, ¹⁰Schneider Children's Medical Center of Israel, Petach Tikva, Israel
Background/Purpose: Systemic-onset juvenile idiopathic arthritis (sJIA) is a pediatric autoinflammatory condition, known for significant variability between patients in its severity and long-term outcomes. The classification…
Abstract Number: 0569 • ACR Convergence 2022
Cytokine Storm Susceptibility Factors IL-18 and Cytotoxic Impairment Converge on Pathologic CD8 T-cell Hyperactivation
Emily Landy¹, Scott Canna², Paul Tsoukas³, Vinh Dang² and Jemy Varghese², ¹University of Pittsburgh, Pittsburgh, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Mounting evidence suggests partial defects in cytotoxicity-related genes may promote hyperinflammation in Macrophage Activation Syndrome (MAS) patients, who uniformly have highly-elevated IL-18. In mice,…
Abstract Number: 0806 • ACR Convergence 2022
Long-term Effectiveness of Sublingual Polybacterial Vaccines in Patients with Systemic Autoimmune Disease and Active Pharmacological Immunosuppression
Inés Pérez Sancristóbal¹, María Paula Álvarez Hernández², Silvia Sanchez - Ramon³, Cristina Martinez⁴, Eduardo de la Fuente³, Concepcion Morado⁴, Dalifer Freites Nuñez², Benjamin Fernandez Gutierrez⁵ and Gloria Candelas⁴, ¹Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain, ²Hospital Clínico San Carlos, Madrid, Spain, ³Department of Clinical Immunology, IML and IdSSC, Hospital Clínico San Carlos, Madrid, Spain, ⁴Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁵Hospital Clínico San Carlos, Rheumatology Deparment, Madrid, Spain
Background/Purpose: Infections in patients with systemic autoimmune disease (SAD) are associated with immune dysfunction, disease activity and immunosuppression. Synthetic and biologic disease-modifying drugs (DMARDs) have…
Abstract Number: 1729 • ACR Convergence 2022
SLAMF4+ CCR5+ Effector Memory CD4+ T Cells Are Polyfunctional, Resistant to Exhaustion, and Expanded in Rheumatoid Arthritis
Mégane Lacaud¹, Houda-Ghozlane Bouzidi¹, Magali Breckler², Delphine Lemeiter², Johanna Sigaux³, Luca Semerano⁴, Marie-Christophe Boissier⁵, Natacha Bessis⁶ and Jerome Biton⁷, ¹Sorbonne Paris Nord University, Inserm U1125, Bobigny, France, ²Sorbonne Paris Nord University, Inserm UMR1125, Bobigny, France, ³Avicenne Hospital, Sorbonne Paris Nord University, Inserm UMR1125, Bobigny, France, ⁴Hopital Avicenne - AP-HP, Sorbonne Paris Nord University, INSERM UMR1125, Bobigny Cedex, France, ⁵INSERM UMR 1125, Sorbonne Paris Nord University,Rheumatology Dpt, APHP, GHUPSSD, Avicenne Hosp, Bobigny, France, ⁶INSERM 1125 and University Sorbonne Paris Nord, Bobigny, France, ⁷INSERM UMR 1125, Sorbonne Paris Nord University, Bobigny, France
Background/Purpose: CD4+ Foxp3- conventional T cells (Tconv) play a key role in the inflammatory process involved in rheumatoid arthritis (RA). Usually, chronic stimulation of T…
Abstract Number: 0581 • ACR Convergence 2022
Mutants Improving Stability Enhance the Potency of Treg-Selective IL-2 Mutein for the Treatment of Autoimmune Disorders
Yingying Hu¹, Hu Ge¹, Yuxi Yan¹, Yun Zhang², Xiaoxing Huang¹, Zhenna Gao², Yiming Kou², Mi Ye², Lei Zhou¹, Siyuan Shao¹, Bowei Yin¹, Zhenzhen Li¹, Yayuan Fu¹, Wenqing Yang¹, Zhuoxiao Cao¹ and Renhong Tang¹, ¹Simcere Pharmaceutical Group, Shanghai, China, ²Simcere Pharmaceutical Group, Nanjing, China
Background/Purpose: Low-dose IL-2 with enhanced sensitivity to Treg cells has been proved to be safe and efficacious in multiple autoimmune disorders (AIDs) including SLE, RA,…
Abstract Number: 0985 • ACR Convergence 2022
S100 Serum Protein Expression Is a Useful Indicator of HCQ Treatment Efficacy in SLE
Risa Wakiya¹, Hiromi Shimada¹, Kiyo Ueeda², Shusaku nakashima¹, Mikiya Kato¹, Taichi Miyagi¹, Yusuke Ushio³, Koichi Sugihara¹, Rina Mino³, mao mizusaki⁴, Kanako Chujo⁵, Tomohiro Kameda¹ and Hiroaki Dobashi⁶, ¹Kagawa University, Miki-cho, Kita-gun, Japan, ²Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ³Kagawa university, Kagawa, Japan, ⁴Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Miki-cho, Kita-gun, Japan, ⁵Kagawa University, Miki, Kita District, Kagawa, Japan, ⁶Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan
Background/Purpose: It is known that type 1 IFN and proinflammatory cytokines are associated with the pathogenesis of systemic lupus erythematosus (SLE). Recently, the S100 protein,…
Abstract Number: 1736 • ACR Convergence 2022
IL-23 Signaling Induces Autoimmune Disease Genes in Mucosal-Associated Invariant T Cells
Tharshana Stephen¹, Ambre Dangien¹, Claire Leloup¹, Ikram Mezghiche¹, Laetitia Camard¹, Hanan Yahia-Cherbal¹, Vincent Guillemot², Natalia Pietrosemoli¹, Hélène Lopez-Maestre¹, Julie Marsande¹, Milena Hasan¹, Dan Cua³, Anne Fourie⁴, Carrie Greving⁵, Raphaelle Parker⁶, Barbara Joyce Shaikh⁷, Bénédicte Oulès⁸, Sarah Guégan⁸, Sélim Aractingi⁸, Elisabetta Bianchi¹ and Lars Rogge¹, ¹Institut Pasteur, Paris, France, ²Institut Pasteur, Paris, Ile-de-France, France, ³Janssen Research and Development, LLC, Spring House, PA, ⁴Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, CA, ⁵Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, ⁶Janssen Research & Development, Janssen-Cilag, Paris, France, ⁷Janssen Research & Development, LLC, San Diego, CA, ⁸Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Genome-wide association studies and mouse models of autoimmune disease have demonstrated an important role of the IL-23 signaling pathway in the pathogenesis of axial…
Abstract Number: 0583 • ACR Convergence 2022
Toll-Like Receptor Ligands Stimulated Monocyte-Derived Langerhans Cell-Like Dendritic Cells Induce Psoriasis-Related Molecules, IL-23 and Delta-Like-4
Rei Takahashi¹, Kohei Maeda¹, Toshihiro Tanioka¹ and Takeo Isozaki², ¹Division of Pathogenesis and Translational Medicine, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan, ²Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
Background/Purpose: Monocyte-derived Langerhans cell-like dendritic cells (Mo-LCs) are involved in epidermal disorders such as psoriasis in murine models. However, the roles of Mo-LCs in the…
Abstract Number: 1048 • ACR Convergence 2022
Nailfold Capillaroscopy and Candidate Biomarker Levels in Systemic Sclerosis-associated Pulmonary Hypertension, Profiling of Non-invasive Markers: A Cross Sectional Study
Jacqueline Lemmers¹, Arjan van Caam², Brigit Kersten², Els Ende, van den², Hanneke KNAAPEN², Arie Dijk, van², Wanda Hagmolen of ten Have², Frank van den Hoogen², Hans Koenen², Sander van Leuven³, wynand Alkema⁴, Ruben Smeets² and Madelon Vonk⁵, ¹Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands, ²Radboudumc, Nijmegen, Netherlands, ³Radboud University, Nijmegen, Netherlands, ⁴Hanze University, Groningen the Netherlands, Dept. Data Science for Life Sciences & Health, Groningen, Netherlands, ⁵Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Pulmonary hypertension (PH) is one of the leading causes of death in Systemic Sclerosis (SSc). Early detection and treatment of PH in SSc is…
Abstract Number: 1741 • ACR Convergence 2022
Mutated Nod2 Controls T Cell Function and Promotes Uveitis in a Blau Syndrome Mouse Model
Leah Huey¹, Kylie Koney¹, Emily Vance¹, Chia-Feng Tsai², Rosalie K. Chu², Marina A. Gritsenko², Ellen Lee¹, Holly Rosenzweig¹ and Ruth Napier¹, ¹Oregon Health & Science University and VA Portland Health Care System, Portland, OR, ²Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA
Background/Purpose: Mutations in the microbial signaling molecule NOD2 cause granulomatous uveitis, arthritis, and dermatitis in Blau Syndrome. We previously showed a novel role for Nod2…
Abstract Number: 0584 • ACR Convergence 2022
Non-Clinical Evaluations of Deucravacitinib and Janus Kinase Inhibitor Specificity in Inflammatory or Homeostatic Pathways
Brandon Johnson, Jennifer Koenitzer, Peter Schafer and Ian M. Catlett, Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib is a selective inhibitor of tyrosine kinase 2 (TYK2) that has shown clinical efficacy in psoriasis, PsA, and SLE. Deucravacitinib is an allosteric…
Abstract Number: 1109 • ACR Convergence 2022
High Interleukin-13 Level Is Associated with Disease Stability in Interstitial Lung Disease
Elena Joerns¹, David Karp¹, Jeffrey Sparks², Traci Adams¹, Una Makris³ and Chad Newton¹, ¹UT Southwestern, Dallas, TX, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Interstitial lung disease (ILD) is a disease of lung parenchyma manifesting with inflammation and fibrosis. Interstitial lung disease (ILD) is a frequent complication of…
Abstract Number: 1745 • ACR Convergence 2022
Effects of Excess IL-18 in Mixed Inflammatory Environments
Vinh Dang¹, Jemy Varghese¹, Emily Landy², Lauren Van Der Kraak², Leonardo Huang¹, Anastasia Frank-Kamenetskii¹ and Scott Canna¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Interleukin 18 (IL-18) is an inflammasome-activated, IL-1 family cytokine that canonically induces interferongamma (IFNg). IL-18 activity is potently inhibited by a soluble, IFNg-inducible antagonist,…
Abstract Number: 0585 • ACR Convergence 2022
Baricitinib Inhibits Proinflammatoly Cytokine Production, Proliferation and Cell Migration in Human Lung Fibroblasts
Takeo Isozaki¹, Rei Takahashi², Kohei Maeda², Toshihiro Tanioka², Kunika Shimizu³, Kazutaka Kawamori³, Noriko Konishi⁴, Shinichiro Nishimi³, Sho Ishii³, Kuninobu Wakabayashi³ and Tsuyoshi Kasama³, ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ²Division of Pathogenesis and Translational Medicine, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan, ³Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Japan, ⁴Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation and joint destruction. Baricitinib is a selective small molecule inhibitor of JAK 1…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].